Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Trial Profile

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Avapritinib (Primary) ; Regorafenib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGER
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 15 Nov 2018 According to a media release, Blueprint Medicines anticipates completing enrollment of the VOYAGER trial in the second half of 2019. The trial permits enrollment of patients with both KIT- and PDGFRA-driven GIST, including patients with the PDGFRa D842V mutation.
    • 24 Sep 2018 According to a Blueprint Medicines media release, data will be presented at 2018 European Society for Medical Oncology (ESMO) Congress
    • 21 Jun 2018 According to a Blueprint Medicines media release, the company has dosed the first patient in the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top